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A b s t r A c t
The treatment of long and diffuse coronary lesions with percutaneous coronary inter-
vention (PCI) has been problematic since the era of plain balloon angioplasty. With 
the advent of bare-metal stents (BMS), long and multiple stents were used to com-
pletely cover the diseased segments in order to improve outcomes. Lesion length 
has been proven to be a factor related to higher rates of restenosis and target le-
sion revascularization (TLR) and the risk was further increased by the multiplic-
ity of implanted stents. Covering the lesion with the least number of non-overlap-
ping stents might reduce the risk of restenosis. This strategy, called spot stenting, 
was initially tested in the BMS era to treat discrete high-grade disease within 
moderately diseased vessel segments and has been shown to significantly reduce 
restenosis rates. Drug-eluting stents (DES) have been consistently shown to re-
duce restenosis and the need for TLR and thus provide improved clinical efficacy 
compared with BMS. However, even with DES, diffuse disease and long lesions 
are still associated with an increased risk of restenosis, need for TLR and major 
adverse cardiac events (MACE). A major long-term concern regarding DES is 
the potential for stent thrombosis which is increased after complex procedures 
with implantation of longer, multiple and overlapping stents. Data are limited but 
recent reports suggest that even when DES are used, selective stenting of only the 
severely narrowed areas of long lesions reduces the risk of MACE compared to 
full lesion coverage. The data supporting the spot stenting approach along with 
some considerations regarding the technique are presented herein. 
t h e  c h A l l e n g e  o f  l o n g  c o r o n A r y  l e s i o n s  
w i t h  d i f f u s e  d i s e A s e
The treatment of long diffuse coronary lesions with percutaneous coronary inter-
vention (PCI) has been problematic. Since the era of plain old balloon angioplasty, 
lesion length has been a factor related to higher rates of restenosis and target 
lesion revascularization (TLR). The advent initially of bare-metal stents (BMS) 
and soon afterwards of drug-eluting stents (DES) reduced TLR but still efficacy 
is suboptimal and safety concerns remain.
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Α .  B a r e  –  m e t a l  s t e n t  p e r i o d 
In the BMS era, multiple and long stent implantation 
for long, diffuse lesions was associated with a high inci-
dence of diffuse in-stent restenosis (ISR).1,2 Diffuse ISR is 
however a major risk factor for malignant recurrent ISR, 
and therefore full lesion coverage with traditional stenting 
is associated with a poor clinical outcome.3 Kobayashi et 
al reported a relationship between length of stented segment 
and restenosis: 24%, 35%, and 47% for segment lengths <20 
mm, 20–35 mm, and >35 mm, respectively.2 The treatment of 
diffuse ISR is exceedingly problematic with recurrence rates 
of 42-80% that frequently necessitate multiple additional PCIs 
or coronary artery bypass grafting.4 The investigators of the 
New Approaches to Coronary Intervention (NACI) registry 
have suggested that stenting of long coronary lesions (>20 
mm) involves significantly higher rates of the need for repeat 
TLR than more discrete lesions. Multivariate analysis showed 
that each 1-mm increase in lesion length was associated with 
an increased relative risk of 1.014 (95% confidence intervals-
CI, 1.004-1.025) for TLR at 1 year.5 A series by Kastrati et 
al examined the contribution of lesion length to restenosis as 
opposed to stent length per se.1 In multivariate analysis, le-
sion length was found to be an independent risk factor for 
restenosis with the risk further increased by multiple and 
overlapping stent placement that were also independent risk 
factors of restenosis. Stented segment length did not show 
any independent effect. It was concluded that long lesions 
represent an independent risk factor for restenosis after 
coronary stent placement and that a possible way to reduce 
the risk would be to cover the lesion with a minimal number 
of non-overlapping stents.1 
Spot stenting, defined as the selective stenting of only 
the most severely narrowed parts of long, diffuse lesions 
has been proposed as an alternative PCI strategy in this set-
ting.6,7 Colombo et al compared spot stenting to a traditional 
stenting strategy for long and diffuse coronary artery disease. 
Outcomes of a consecutive series of 130 long lesions (>15 
mm) in 101 patients treated with intravascular ultrasound 
(IVUS) guided PCI and spot stenting were compared with 
those of a traditionally stented matched group of patients. 
Coronary angioplasty was performed with a balloon to vessel 
ratio of 1:1, according to the IVUS media-to-media diameter 
of the vessel at the lesion site, to achieve prespecified IVUS 
criteria: lumen cross-sectional area ≥5.5 mm² or ≥50% of the 
vessel cross-sectional area at the lesion site. The stents were 
implanted only in the vessel segments where the IVUS criteria 
were not met. In the spot stenting group, stents were implanted 
in 67 of 130 lesions, and the mean stent length was shorter 
than that of lesions in the matched traditional stenting group 
(10.4±13 mm vs. 32.4±13 mm, p <0.005). The 30-day major 
adverse cardiac event (MACE) rate was similar (5%) for both 
groups. Angiographic restenosis was 25% with spot stenting, 
as compared with 39% with the usual technique (p <0.05). 
At 6-month follow-up, MACE and TLR rates were lower 
with spot stenting (22% vs. 38%; p <0.05 and 19% vs. 34%, 
p <0.05 respectively). Thus, IVUS guided spot stenting with 
BMS was associated with good acute outcome and significantly 
reduced angiographic restenosis and follow-up adverse event 
rates compared to traditional stenting.6
Β .  d r u g - e l u t i n g  s t e n t  p e r i o d
Randomized clinical trials and registries which included 
complex coronary lesions found that DES reduce the need 
for revascularization and thus provide superior clinical 
efficacy in routine practice compared with BMS.8 DES 
implantation for small vessel disease or long lesions with 
multiple stents is efficacious for reduction of restenosis 
rates and TLR rates compared with BMS implantation.9,10 
In the DES era, interventionalists implant stents to cover 
the entire atherosclerotic lesion, that is, the stented seg-
ment length tends to be longer than the lesion length and 
the use of multiple, overlapping DES has been considered a 
suitable approach in clinical practice.11,12 However, stent length, 
number of stents, and the use of overlapping stents have all 
been associated with an increased risk of restenosis, thombosis 
and stent fracture.13-16 Coronary artery lesion length is still an 
independent predictor of restenosis following PCI with DES.17 
Recently, Raber et al reported an increased risk of both TLR 
and composite end-point of death and myocardial infarction in 
patients with overlapping DES compared to patients with single 
or multiple, but not overlapping stents.14 DES overlap occurs in 
>10% of patients undergoing PCI in routine clinical practice 
and is associated with impaired angiographic and long-term 
clinical outcome, including death or myocardial infarction.14 
Notably, stent thrombosis has been shown to occur very 
long after the index procedure.15 In the Bern and Rotterdam 
study, stent thrombosis was reported to occur in a continuous 
rate of 0.4-0.6% per year for up to 4 years without diminution.18 
Previous data including a meta-analysis of 10 randomized 
studies demonstrated that stent length is a risk factor for 
acute and late stent thrombosis and MACE.19 Suh et al also 
reported that stent length was one of the predictors of stent 
thrombosis and that the threshold of stent length for predicting 
DES thrombosis was 31.5 mm.20 The SYNTAX trial showed 
a stent thrombosis rate of 3.3% at 1 year which suggests 
that complex procedures with implantation of longer and 
multiple DES to treat multi-vessel disease and fully cover 
atherosclerotic lesions may be associated with an increased 
risk for stent thrombosis.21 Polymer hypersensitivity reactions, 
positive remodeling with late acquired malapposition, delayed 
arterial healing, late stent fracture, and endothelial dysfunc-
tion are a few of the possible causes of the increased risk of 
very late stent thrombosis with first generation DES.22,23 It has 
been shown that even a small (>0.14%/year) incremental risk 
of thrombosis with DES might be sufficient to outweigh the 
benefit of restenosis prevention and favor BMS use for the 
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overall PCI population.24 To address these issues concerning 
first generation DES, new DES have been developed with 
novel materials, designs, and delivery systems, with improved 
biocompatible polymers, and new antiproliferative agents 
compared with their predecessors. 
Because treatment of hemodynamically non significant 
lesions is not indicated, the adoption of selective stenting 
with DES of only hemodynamically significant stenoses in 
the context of diffuse disease with variable severity is logical 
in clinical terms. Katritsis et al compared spot stenting to a 
strategy of full stent coverage for long and diffuse lesions 
when first generation DES are used.25 Consecutive patients 
(n=179) with long (>20 mm) coronary lesions of non uniform 
severity and indication for PCI were randomized to full lesion 
coverage with multiple, overlapping stenting or spot stenting 
of hemodynamically significant lesion parts only, defined as 
diameter stenosis >50% as measured by quantitative coronary 
angiography (QCA). At 1-year follow-up, MACE were signifi-
cantly fewer among patients with spot stenting compared to 
full coverage with DES (5.6% vs 15.6%, p = 0.031). At 3 years, 
MACE were also significantly fewer (7.8% vs 20%, p=0.019) 
and a Cox proportional hazard model showed that the risk for 
MACE was almost 60% lower in patients with spot stenting 
compared to those with full stenting (hazard ratio 0.41, 95% 
CI 0.17 - 0.98, p = 0.044).25 The results were similar at long-
term follow up (2-7 years) when it was demonstrated that the 
risk for MACE was almost 65% lower among patients with 
spot stenting.26 The authors concluded that in the presence 
of diffuse disease of non uniform severity, selective stenting 
of only the significantly narrowed parts of the lesion confers 
better long-term results compared to total lesion coverage 
with first generation DES.
d i s c u s s i o n
The abovementioned data, albeit limited, indicate that a 
minimalistic approach of spot stenting is preferable to the “full 
metal jacket” or “normal to normal” approach with both BMS 
and DES. As stented length increases the risk for restenosis and 
stent thrombosis also increases, since the innate morphology 
and physiology are disrupted by unnecessary metal, polymer 
and drug. It is a fact that in diffuse and uniformly severe disease 
full lesion coverage with stents is frequently necessary (Fig. 
1). The comparison of spot stenting to full stent coverage is 
meaningful for long and diffuse lesions of non uniform severity. 
The studies are limited and there is no study comparing the two 
techniques with second generation DES, which are at least as 
effective and probably safer compared to first generation DES. 
This has been demonstrated in a recently published network 
meta-analysis of 49 randomized controlled trials (including 
50844 patients) comparing PCI outcomes between different 
DES or between DES and BMS. Second generation cobalt – 
chromium everolimus –eluting stents had the lowest rate of 
stent thrombosis within 2 years of implantation compared to 
first generation DES but also compared with BMS.27 If this 
finding is confirmed in further randomized trials, it would 
be a paradigm shift. Furthermore, recent data suggest that 
Figure 1. a. An example of long, diffuse and uniformly severe disease of the left anterior descending artery, responsible for an 
acute coronary syndrome with anterior wall ischemia. B. The lesion was treated by full lesion coverage with DES since in this case 
spot stenting was not possible.
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compared to durable polymer everolimus-eluting DES, other 
second generation DES, such as zotarolimus and biolimus 
eluting, are probably equally safe and effective, making a class 
effect possible regarding this issue.28,29 For the time being, 
data are lacking to answer the question whether spot stenting 
would still be preferable to full lesion coverage when second 
generation DES are used. The same question should also be 
answered for DES with bioabsorbable polymer and for the 
upcoming fully bioabsorbable DES.
A traditional “normal to normal” stenting approach is sim-
pler, probably faster, less intellectually demanding and perhaps 
leads more easily to an optically “perfect” angiographic result. 
However, even with the limited existing data, spot stenting 
has been shown to be superior because optimal outcomes are 
obtained if stents are implanted only to treat functionally signifi-
cant disease as shown in the FAME trial.30 In this multi-center 
trial, 1005 patients with multi-vessel disease were randomized 
to undergo PCI with implantation of DES either guided by 
angiography alone or guided by functional flow reserve (FFR) 
measurements in addition to angiography. Patients assigned to 
angiography-guided PCI underwent stenting of all indicated 
lesions, whereas those assigned to FFR-guided PCI underwent 
stenting of indicated lesions only if the FFR was ≤0.80. At 1 
year, MACE and each of their individual components (death, 
myocardial infarction and the need for repeat revasculariza-
tion) were reduced by 30% - 40% in patients randomized to 
FFR-guided PCI compared with those randomized to standard 
angiographic guidance. Furthermore, patients randomized to 
angiography guidance had PCI performed on a significantly 
greater number of lesions, resulting in greater stent number 
and length.30 At two years of follow-up, the superiority of FFR-
guided versus angiography-guided PCI persisted as combined 
rates of death, nonfatal myocardial infarction, and revascu-
larization were 17.9% versus 22.4%, respectively. For lesions 
deferred on the basis of FFR >0.80, the rate of myocardial 
infarction was 0.2% and the rate of revascularization was 3.2% 
after 2 years (Table 1).31 The value of FFR to guide stenting 
decisions was also demonstrated by the recent publication of 
FAME 2 trial where in patients with stable coronary artery 
disease and functionally significant stenoses, FFR-guided PCI 
plus the best available medical therapy decreased the need for 
urgent revascularization as compared with the best available 
medical therapy alone.32 The FAME 1 and 2 trials established 
FFR as the best currently available method to evaluate the 
functional significance of coronary lesions and therefore FFR 
is recommended for PCI guidance in stable patients in the 
recent myocardial revascularization guidelines.33
In the main studies comparing spot stenting to traditional 
stenting, Colombo et al used IVUS, while Katritsis et al used 
QCA for spot stenting guidance.6,25 However, these techniques 
are not accurate to assess the physiologic significance of le-
sions. QCA is inherently inferior to IVUS and as very recently 
shown in the FIRST study anatomic measurements by IVUS 
taBle 1. Results of the FAME trial at 1 and 2 years.30,31
Angiography  
guided PCI
FFR guided 
PCI
Stenting All lesions If FFR ≤0.80
Stents per patient 2.7±1.2 1.9±1.3
1- year MACE* 18.3% 13.2%
2- year MACE* 22.4% 17.9%
FFR = functional flow reserve; MACE = major adverse cardiac 
events; PCI = percutaneous coronary intervention 
*MACE: Death, non fatal myocardial infarction or repeat revas-
cularization.
show only a moderate correlation with the FFR values, while 
the optimal cutoff for an IVUS measured minimal lumen area 
to detect FFR ≤0.80 is vessel diameter dependent and not yet 
adequately standardized and validated.34 Concerning diffuse 
disease it should be noted that FFR is not only a means to gain 
a functional assessment per vessel but also per vessel segment 
and thus can guide complex PCI in case of diffuse disease.35 
In the FAME trial, FFR was measured with a coronary pres-
sure guidewire at maximal hyperemia induced by intravenous 
adenosine, administered at a rate of 140 μg/kg/min through a 
central vein. In the case of diffuse atherosclerosis punctuated 
by focal areas of more severe stenosis, or in the case of more 
than one stenosis within the same artery, pressure pullback 
recordings during hyperemia were performed and stenting 
was indicated for lesions with sudden pressure drops (ΔΡ>10-
15 mmHg) during pullback (Table 2).30,35 FFR is therefore a 
technique supported by robust clinical data that can guide 
a spot stenting approach. It should be noted that it is not 
indicated for PCI in cases of patients with acute myocardial 
infarction nor to evaluate the hemodynamic significance of 
infarct-related artery stenoses for several days post-infarction, 
since FFR would be high because of stunning and edema of 
the infarcted territory.36 After their resolution, which means at 
least 5 days later depending on the infarct extent and patient 
related factors, FFR could be applied with a similar ischemia 
threshold value as in stable patients to assess the hemodynamic 
significance of residual or recurrent stenoses.36,37 
Further anatomic details provided by intracoronary imaging 
techniques such as IVUS (Fig. 2) or even better optical coher-
ence tomography (OCT), which has a much higher resolution, 
could further optimize spot stenting PCI by controlling for 
inadequate stent apposition, tissue protrusion, intraluminal 
thrombus and edge dissection.38 Near-infrared spectroscopy 
(NIRS) combined with IVUS is also a promising novel imaging 
modality that could add to spot stenting technique precision 
in order to avoid incomplete coverage of lipid core plaques 
and thus minimize the risk of intra-procedural complications 
and post-procedural adverse events.39 It should be kept in 
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taBle 2. Algorithm for FFR use to guide spot stenting in non uniform diffuse disease with serial lesions.30,35
1) Advance pressure wire at the 
most distal part of the coronary 
artery
2) Induce hyperemia by IV 
adenosine and measure FFR
If FFR >0.80 à no stenting is needed.
If FFR ≤0.80 à proceed to pullback under fluoroscopy 
3) Decision to stent according to 
pullback results
If the pressure decline is gradual due to diffuse disease à optimal medical treatment 
If sudden pressure drops (ΔΡ>10-15 mmHg) are found during pullback à spot stent
4) Stenting sequence The most “severe spot” should be stented first and pullback repeated to check the other lesions
By stenting the most severe lesion the gradient of other lesions may increase. This is much more 
common when distal lesions are stented first than vice versa
5) Control Check the final result with another final pullback recording to check stented and other artery 
segments. Measure final distal FFR
FFR = functional flow reserve
Figure 2. Spot stenting example. 
A & b: Proximal and mid LAD 
segments are diffusely diseased 
but there is more severe narrowing 
just distal to the first septal branch 
(panel A, arrow) and at the distal 
LAD (panel b, arrow). c & d: Fol-
lowing IVUS which was performed 
to determine the length of the 
stent for proximal and mid LAD, 
a 3×12 mm stent was implanted 
to treat only the focal proximal le-
sion and a 2.5×9 mm stent to treat 
the focal distal lesion and the final 
results are shown in panels c & d 
(white parallel lines).
mind though that intracoronary imaging modalities always 
add considerably to the procedural cost and their use (if, which 
one and why) depends on availability and should be decided 
on a case-by-case basis.
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c o n c l u s i o n
A minimalistic approach of spot stenting seems preferable 
to the “full metal jacket” approach for PCI in case of long 
lesions and diffuse coronary artery disease. As stented length 
increases the risk for restenosis and stent thrombosis increases 
since metal, polymer and drug disrupt the innate morphology 
and physiology. Angiography ± QCA, IVUS, OCT, NIRS and 
FFR can help guide the spot stenting approach depending on 
the experience of each catheterization laboratory. Stents should 
be implanted only to treat functionally significant disease, 
which is best documented by FFR that can reliably measure 
the functional significance of lesions per vessel but also per 
vessel segment. Spot stenting could be further optimized by 
the use of intracoronary imaging techniques which should be 
decided on a case-by-case basis.
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